Printed from Voxsanity (voxsanity.com.au) — NCT07570810 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 2 Diabetes
Type 2 Diabetes Trial, Not Yet Recruiting
NCT07570810
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 to 65 years, male or female.
- A liver fat content of 10% or more, measured by a specific type of MRI scan within the 3 months before joining the trial.
- A diagnosis of type 2 diabetes.
- A blood sugar control measure (HbA1c) between 7.0% and 10.5%.
- A fasting blood sugar level between 7.0 and 13.3 mmol/L.
- A body mass index (BMI) between 30 and 45 kg/m².
- Blood sugar managed through lifestyle changes only (such as diet and exercise), with no diabetes medication, for at least 3 months before screening.
- Willingness to keep diet and exercise habits consistent throughout the study, take the study medication as directed, and regularly check and record blood sugar levels.
- Ability to understand the study, follow the study plan, and sign a consent form voluntarily.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Certain abnormal blood test results, including raised liver enzyme levels, raised bilirubin, raised creatinine, reduced kidney filtration rate, low platelet count, abnormal clotting levels, or low albumin (confirm with trial site for specific values).
- Use of any blood sugar–lowering medication in the 3 months before joining the trial.
- Weight loss of 5% or more in the 3 months before joining, or 10% or more in the 6 months before joining, or current use of weight-loss drugs, corticosteroids, or similar medications.
- A history of allergic reactions to a class of diabetes medications called GLP-1 receptor agonists, currently being in an allergic state, having allergic conditions, or having a history of allergies to two or more substances.
- Having type 1 diabetes, a rare single-gene form of diabetes, diabetes caused by pancreatic damage, or another secondary form of diabetes.
- A history of severe itching (pruritus).
- Diabetic eye disease (retinopathy or maculopathy) that is uncontrolled or potentially unstable.
- A personal or family history of a type of thyroid tumour called thyroid C-cell tumour, or a personal or family history of multiple endocrine neoplasia type 2.
- A history of acute or chronic inflammation of the pancreas (pancreatitis).
- Moderate or severe liver scarring (cirrhosis), classified as Child-Pugh grade B or C.
- A positive test result for hepatitis B, hepatitis C, HIV, or syphilis.
- Certain heart rhythm problems, including a specific electrical measurement of the heart (QTc interval) that is too long, or any heart or cardiovascular condition that the researcher determines makes participation unsuitable.
- Any condition that affects how the body absorbs, distributes, processes, or removes medications (confirm with trial site).
- Any digestive (gastrointestinal) condition that affects how food is broken down and absorbed.
- Use of certain medications that strongly affect a liver enzyme called CYP3A4 within 14 days before joining or at any point during the trial (confirm with trial site for specific medications).
- A history of cancer (malignant tumour) within the 5 years before joining the trial.
- Three or more serious low blood sugar episodes in the 12 weeks before starting the trial, or a severe blood sugar-related emergency in the same period.
- Drug or alcohol misuse in the 6 months before joining the trial.
- Blood pressure that is not well controlled.
- A diagnosed mental illness or epilepsy.
- An uncontrolled severe infection at the time of joining the trial.
- Currently pregnant, planning to become pregnant, or breastfeeding.
- Participation in another clinical trial in the 3 months before joining this trial.
- Any other condition that the researcher judges would make participation unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: +86-13524640378
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
30 November 2026
Primary endpoints
Percentage change in body weight relative to baseline; Changes in energy expenditure
Can't join this trial?
Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.